With years of experience in Bioengineering Chris Adams PhD is QuantuMDx’s Head of Biosensor. He began his career in 1994 at the University of Glasgow where he gained his PhD in Physics. Having always been fascinated by science he began his career by supporting the development of the early outreach and infrastructure for Glasgow science centre. The crossover between physics, engineering and medical sciences happened in 2003 whilst he was involved in developing ASICs and novel fabrication techniques on flexible, biocompatible and implantable electronics for retinal prosthesis and direct cell-electronic coupling. More recently he has been involved in intracellular silicon lab-on-chip applications and ultrafast imaging of neural communication pathways to understand neural networks and cortical signalling. He currently leads QuantuMDx’s Biosensor team, helping develop the sensor architectures, active electronics and signal processing for specific biological target recognition. Chris has a wealth of experience working in academic, research and commercial environments having held senior positions multiple successful start-up companies, he has more than 10 publications and multiple patent applications.
TB or not TB
Wednesday, 11 October 2017 at 13:30
Add to Calendar ▼2017-10-11 13:30:002017-10-11 14:30:00Europe/LondonTB or not TBBiodetection and Biosensors 2017 in Murray Edwards College, Cambridge, UKMurray Edwards College, Cambridge, UKSELECTBIOenquiries@selectbiosciences.com
With 8.6 million new cases diagnosed every year, and an estimated 3 million unreported cases in remote village locations, TB is still a leading cause of death worldwide. This, combined with increasing levels of drug resistance, means that the need for a portable device able to deliver accurate 15-20 minute turnaround DNA-based classification is ever more acute. Chris Adams, Head of Biosensor Development at QuantuMDx, will present the company’s development of a handheld sample-to-result device that will make personalised medicine affordable and accessible, even in resource scarce settings. The device delivers referral laboratory-standard results at the point of care. It is operated simply and with on-board power. The device performs DNA extraction, PCR and either multiplex label-free microarray detection using a silicon nanowire or optical based assays QuantuMDx has also developed a novel DNA sequencing technology for possible de novo or discovery application of the technology in the future. Excitingly the company has recently hit the significant milestone of full integration of the platform in an beta prototype. Clinical trials are expected to kick off later this year, with commercialisation expected in 2018.
Add to Calendar ▼2017-10-10 00:00:002017-10-11 00:00:00Europe/LondonBiodetection and Biosensors 2017Biodetection and Biosensors 2017 in Murray Edwards College, Cambridge, UKMurray Edwards College, Cambridge, UKSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2017-10-11 13:30:002017-10-11 14:30:00Europe/LondonTB or not TBBiodetection and Biosensors 2017 in Murray Edwards College, Cambridge, UKMurray Edwards College, Cambridge, UKSELECTBIOenquiries@selectbiosciences.com
